CFTR and respiratory tract infectious disorder: Although the recent introduction of novel therapies targeting the defective CF transmembrane conductance regulator (CFTR) protein has transformed the landscape of CF [17,18], the antibiotic treatment of respiratory infections will remain the mainstay of CF therapy for the foreseeable future [19,20].